tiprankstipranks
Trending News
More News >
Biohaven Ltd. (BHVN)
NYSE:BHVN
US Market

Biohaven Ltd. (BHVN) AI Stock Analysis

Compare
607 Followers

Top Page

BH

Biohaven Ltd.

(NYSE:BHVN)

Rating:40Underperform
Price Target:
Biohaven Ltd.'s overall stock score is low due to substantial financial challenges, including zero revenue and negative cash flow. Technical analysis indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio. However, the recent $600 million investment provides a positive outlook by supporting clinical developments. Despite this, the overall risks remain significant, making the stock a cautious investment.
Positive Factors
Drug Approval
Troriluzole would represent the first FDA-approved therapy for the treatment of SCA, highlighting its potential significance in the market.
Pipeline Expansion
Biohaven's pipeline is considered one of the most expansive in smidcap biotech, attracting significant investor interest.
Research and Development
Biohaven delivered another solid R&D Day with all programs moving forward as planned, and everything heard continues to support a positive investment thesis on the stock.
Negative Factors
Investor Skepticism
New data to address areas of investor skepticism showed very low incidence of CNS-AEs, which may serve as a point of competitive differentiation.
Regulatory Delays
The FDA recently extended the PDUFA date for the NDA of troriluzole in SCA by 3 months, indicating potential regulatory delays.

Biohaven Ltd. (BHVN) vs. SPDR S&P 500 ETF (SPY)

Biohaven Ltd. Business Overview & Revenue Model

Company DescriptionBiohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
How the Company Makes MoneyBiohaven Ltd. generates revenue primarily through the sale of its pharmaceutical products designed to treat neurological and neuropsychiatric diseases. The company's key revenue streams include sales from its approved drugs, particularly in the migraine treatment market. Biohaven may also earn income through licensing agreements, where it partners with other pharmaceutical companies to distribute its products in various regions. Additionally, the company could be involved in collaborative research and development agreements, which may provide milestone payments and royalties, contributing to its earnings.

Biohaven Ltd. Financial Statement Overview

Summary
Biohaven Ltd. faces financial challenges with zero revenue and significant operational losses. The balance sheet is stable but lacks growth, and cash flow remains negative with reliance on financing. Overall, financial health is weak, requiring revenue growth and improved cash generation.
Income Statement
15
Very Negative
Biohaven Ltd. has consistently reported zero revenue in recent years, indicating a lack of product sales or service income. The company has faced significant losses with net income remaining negative, reflecting ongoing operational challenges. This lack of revenue generation alongside substantial losses results in a low income statement score.
Balance Sheet
35
Negative
The balance sheet reveals a relatively stable equity position with stockholders' equity remaining positive. However, the debt-to-equity ratio has been manageable due to low levels of debt. Despite positive cash balances, the company’s equity ratio is impacted by limited asset growth. The overall financial position is stable but lacks significant improvement, contributing to a moderate score.
Cash Flow
25
Negative
Operating cash flow is consistently negative, indicating ongoing cash outflows from core operations. Free cash flow remains negative, reflecting challenges in generating cash after capital expenditures. The cash flow score is limited by the lack of positive cash generation, although financing inflows have supported liquidity.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.000.000.000.00462.51M0.00
Gross Profit
-977.00K0.00-3.37M-1.39M370.85M-72.00K
EBIT
-923.43M-885.11M-436.05M-567.93M-218.90M-114.51M
EBITDA
-917.02M-841.76M-429.14M-462.80M-217.51M-114.43M
Net Income Common Stockholders
-888.60M-846.42M-408.17M-570.28M-213.80M-118.67M
Balance SheetCash, Cash Equivalents and Short-Term Investments
322.75M485.99M381.82M465.34M76.06M82.51M
Total Assets
458.95M615.11M513.21M661.78M142.06M111.50M
Total Debt
30.80M36.58M30.88M30.58M626.72M267.46M
Net Debt
-67.61M-62.55M-217.53M-174.30M550.66M184.95M
Total Liabilities
199.45M191.67M85.24M123.01M47.37M34.72M
Stockholders Equity
259.50M423.44M427.98M538.77M34.69M16.78M
Cash FlowFree Cash Flow
-649.01M-586.50M-334.77M-338.76M-146.78M-78.65M
Operating Cash Flow
-644.94M-582.45M-331.73M-297.69M-145.84M-75.96M
Investing Cash Flow
-114.13M-244.97M129.83M-304.79M944.00K-2.70M
Financing Cash Flow
674.72M677.77M211.91M767.60M138.45M152.24M

Biohaven Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price16.79
Price Trends
50DMA
18.58
Negative
100DMA
26.69
Negative
200DMA
35.49
Negative
Market Momentum
MACD
-0.92
Negative
RSI
39.42
Neutral
STOCH
64.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BHVN, the sentiment is Negative. The current price of 16.79 is above the 20-day moving average (MA) of 16.03, below the 50-day MA of 18.58, and below the 200-day MA of 35.49, indicating a bearish trend. The MACD of -0.92 indicates Negative momentum. The RSI at 39.42 is Neutral, neither overbought nor oversold. The STOCH value of 64.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BHVN.

Biohaven Ltd. Risk Analysis

Biohaven Ltd. disclosed 60 risk factors in its most recent earnings report. Biohaven Ltd. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Disruptions at the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions, which could negatively impact our business and the approval of an NDA, BLA or similar application. Q4, 2024

Biohaven Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
$2.17B-3.81%59.45%-290.38%
55
Neutral
$2.19B48.01-16.56%53.40%-230.86%
54
Neutral
$2.45B-31.51%
54
Neutral
$5.37B3.35-45.10%2.79%16.77%-0.01%
52
Neutral
$1.66B-70.58%100.03%64.22%
49
Neutral
$1.73B-33.98%449.03%42.86%
40
Underperform
$1.71B-316.82%-65.63%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BHVN
Biohaven Ltd.
15.69
-18.06
-53.51%
LGND
Ligand Pharma
115.39
35.24
43.97%
KNSA
Kiniksa Pharmaceuticals
30.22
11.29
59.64%
ARQT
Arcutis Biotherapeutics
13.73
5.63
69.51%
TARS
Tarsus Pharmaceuticals
40.96
8.22
25.11%
NAMS
NewAmsterdam Pharma Company
20.50
0.70
3.54%

Biohaven Ltd. Corporate Events

Private Placements and Financing
Biohaven Ltd. Secures $600M Investment from Oberland Capital
Positive
Apr 28, 2025

On April 28, 2025, Biohaven Ltd. announced a Note Purchase Agreement with Oberland Capital for an investment of up to $600 million, with an initial tranche of $250 million to be funded shortly after the closing date. This agreement aims to support Biohaven’s clinical trials and commercialization efforts, particularly for troriluzole, a potential treatment for spinocerebellar ataxia, pending FDA approval. The deal reflects Oberland Capital’s confidence in Biohaven’s innovative therapeutic portfolio and its potential to address unmet needs in rare diseases.

Spark’s Take on BHVN Stock

According to Spark, TipRanks’ AI Analyst, BHVN is a Underperform.

Biohaven Ltd. is in a challenging financial position with no revenue and negative cash flow, resulting in a low financial performance score. Technical indicators suggest bearish momentum, and the valuation reflects the absence of profitability. These factors contribute to a low overall stock score, highlighting significant risks in investing.

To see Spark’s full report on BHVN stock, click here.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.